Recognizing the potential translational values of PLCG2 inhibitors, we will further evaluate the efficacy and clinical feasibility of PLCG2 inhibitors alone or in combination with ICB therapy in preclinical animal models of CRC. This evidence concerns the gene PLCG2 and colorectal carcinoma.